Skip to main content

Partners

Welcome to contact Moberg Pharma for collaboration/licensing in the following projects:

  • MOB-015 - Onychomycosis (nail fungus) – Registration preperations are ongoing
    MOB-015 is a new topical treatment for onychomycosis (nail fungus) with antifungal, keratolytic, and emollient properties. The company’s patented formulation technology facilitates delivery of high concentrations of a proven antifungal substance (terbinafine) into and through the nail. Since MOB-015 is applied locally, adverse events associated with oral treatments can be avoided. The company estimates the sales potential of MOB-015 to USD 250–500 million annually.

    Several attractive licensing agreements for MOB-015 are already in place in Europe (Bayer), Japan (Taisho), South Korea (Dongkoo) and Canada (Cipher) and we look forward to entering into more exciting partnerships in the future.

Contact: bd@mobergpharma.se